Latest News — Page 8
Clinical Practice
US Cancer Drug Shortages Persist at Every Major Cancer Center, NCCN Finds
Every NCCN academic cancer center now reports a shortage of at least one anticancer medicine, led by ifosfamide (94%) and carboplatin (71%). Pharmacy directors say three years of policy have not moved the problem. #SyenzaNews #DrugShortages #Oncology #MarketAccess
Clinical Practice
NICE Draft Guidance Rejects Lenacapavir for HIV PrEP in England
NICE has opened consultation on draft guidance that does not recommend lenacapavir for HIV PrEP, finding the six-monthly injection is not value for money for the NHS in England. #SyenzaNews #HTA #HIV #PrEP #MarketAccess
Artificial Intelligence And Machine Learning
AI in health technology assessment: what stays human
Alec Morton of NUS explains how AI is changing health technology assessment, what stays human, and why cheaper analysis could mean more health economics.
Europe
Rewarding Quality, Not Just Price: What the EU Public Procurement Act Means for Medicines
The European Commission’s EU Public Procurement Act would make quality, not price, the default for public tenders. EFPIA supports the shift, with one warning: resilience should not become local-content rules. #SyenzaNews #EUProcurement #Medicines #MarketAccess #HealthPolicy
Artificial Intelligence And Machine Learning
UK AI Healthcare Commission Report Calls for L-Plates Regulation
An independent UK commission has published its recommendations for regulating AI in healthcare. The report calls for staged approvals and continuous real-world monitoring, alongside stronger enforcement powers for the MHRA. #SyenzaNews #AI #Healthcare #MarketAccess
Artificial Intelligence And Machine Learning
AI in Portuguese Healthcare: What Should Portugal Want It to Do?
Nova SBE’s Saúde em Perspetiva podcast asks what Portugal’s National Health Service should want from AI, and where the red lines sit. #SyenzaNews #DigitalHealth #AIinHealthcare
Biologics And Biosimilars
Sandoz Bio100 Biosimilars Plan Targets 100 Products by 2040 and Doubles 2025 Sales by 2035
Sandoz has put a date on its golden decade for biosimilars. The Bio100 plan targets more than 100 biosimilars by 2040, about 80% coverage of biosimilar-addressable LoE value from 2035, and a doubling of 2025 net sales. #SyenzaNews #MarketAccess #Biosimilars #ValueCreation
Clinical Practice
Semaglutide Linked to Fewer Asthma Attacks and COPD Exacerbations in UK Records
Real-world UK data presented at ERS 2026 link semaglutide to fewer asthma attacks and COPD exacerbations. The indication stays metabolic, but the signal raises a real question for value and access teams. #SyenzaNews #MarketAccess #GLP1 #Respiratory
Clinical Practice
FDA Grants Accelerated Approval to Camizestrant for ESR1-Mutated Breast Cancer
Camizestrant (Etcamah) gains accelerated FDA approval for ESR1-mutated advanced breast cancer, with median progression-free survival of 16 months versus 9.2 months in SERENA-6. #SyenzaNews #BreastCancer #FDA #Oncology
Diseases
South Africa Initiates 55,123 People on Twice-Yearly Lenacapavir PrEP
South Africa has initiated 55,123 people on twice-yearly lenacapavir PrEP in the programme’s first 94 days. Demand is strongest in Gauteng and KwaZulu-Natal; branded supply, second-dose retention and the 2027 generic tender are the real constraints. #SyenzaNews #HIVPrevention #Lenacapavir #MarketAccess
Diseases
Novartis and The Max Foundation Mark 25 Years of Cancer Access in LMICs
Novartis and The Max Foundation mark 25 years of partnership that has delivered cancer treatment to more than 100,000 patients across 71 LMICs. The next test is whether the model can carry a broader oncology portfolio and transition to country funding.
#SyenzaNews #MarketAccess #GlobalHealth
Clinical Practice
Six Proteomic Aging Clocks Detect Age Reversal With Rentosertib
An Insilico Medicine phase 2a trial found six proteomic aging clocks all detected lower biological age in patients treated with rentosertib, an AI-designed drug for idiopathic pulmonary fibrosis. #SyenzaNews #Proteomics #AgingClocks #DrugDiscovery #IPF
Cardiovascular And Metabolic Diseases
Novo Nordisk Halts Ziltivekimab Cardiovascular Programme After Futility Review
Novo Nordisk has stopped the two remaining ziltivekimab heart failure trials after a futility review, leaving ARTEMIS as the last anti-inflammatory cardiovascular outcomes bet. #SyenzaNews #MarketAccess #Cardiology #HTA
Clinical Practice
Aspen Exits Lenacapavir Local Manufacturing, Backs Merck’s Monthly Oral PrEP
Aspen Pharmacare has walked away from local lenacapavir manufacturing over the lack of guaranteed volumes, and is instead backing Merck’s once-monthly oral PrEP pill, alimatravir. #SyenzaNews #HIV #PrEP #MarketAccess
Diabetes
Aspen Pharmacare Bets on Manufacturing Rebound and Generic Semaglutide
Aspen Pharmacare posted 22% normalised earnings growth and is betting on a manufacturing rebound and a generic semaglutide rollout for FY2027. #SyenzaNews #Pharma #GLP1 #MarketAccess #SouthAfrica
Clinical Practice
Trump’s MFN Drug Pricing Policy Is Cutting Europe’s Access to New Medicines
Trump’s Most Favored Nation drug pricing policy is already delaying new medicine launches in Europe. Brussels journalist Christoffer Frendesen unpacks the silence, the data, and why it may outlast the Trump presidency. #SyenzaNews #MarketAccess #DrugPricing